Video

ESMO 2026: Highlights and analysis

Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer

Lifileucel plus pembrolizumab shows durable responses in first-line advanced melanoma

T-cell engagers in mAPMR/mCRPC

Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer

Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer

ESMO 2026: Advances in NMIBC and MIBC

Perioperative apalutamide plus ADT improves event free survival in high risk localised prostate cancer

AI-based digital MammaPrint assay predicts recurrence risk and survival in early-stage breast cancer

UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma